podofilox
RxCUI 8463
RxNorm ingredient and formulation relationships
Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.
Podophyllotoxin
Podophyllotoxin (PPT) is the active ingredient in Podofilox, a medical cream used to treat genital warts and molluscum contagiosum. It is not recommended for HPV infections without external warts. It can be applied either by a healthcare provider or the patient themselves. Podophyllotoxin is a non-alkaloid lignan extracted from the roots and rhizomes of plants of the genus Podophyllum. A less refined form known as podophyllum resin is also available, but has greater side effects. Podophyllotoxin was first isolated in pure form in 1880 by Valerian Podwyssotzki (1818 – 28 January 1892), a Polish-Russian privatdozent at the University of Dorpat (now Tartu, Estonia) and assistant at the Pharmacological Institute there. PPT is on the World Health Organization's List of Essential Medicines.
Background only. Canonical identity remains RxNorm; clinical-trial relationships come from ClinicalTrials.gov.Conditions being studied
Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.